Francisco Ayala
YOU?
Author Swipe
View article: Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Nonauthor Collaborators
View article: Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Receiver operating characteristics (ROC) curves data of FOXC1 Score (VFOXC1) versus IHC phenotype and PAM50 intrinsic subtype in basal-like/non-basal categories definitions
View article: Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of disease-free survival (DFS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Forest plot for the GEICAM_CIBOMA translational study cohort primary endpoint of recurrence-free survival (RFS) on the capecitabine arm versus observation arm for basal-like/non-basal categories variables
View article: Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Purpose:In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non–basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from adj…
View article: Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of 5-year and 8-year recurrence-free survival (RFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Inter-assay agreement assessment by Kappa index between basal-like/non-basal categories variables
View article: Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Patient’s distribution by VFOXC1 and Ki67
View article: Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of overall survival (OS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Disease-free survival (DFS) events for basal-like/non-basal subpopulations by VFOXC1 in the GEICAM_CIBOMA translational analysis
View article: Supplementary Table S7 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S7 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of overall survival (OS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of disease-free survival (DFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S5 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S5 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of distant relapse-free survival (DRFS) for VFOXC1 plus Ki67 IHC subgroups in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Patient’s distribution by the standardized FOXC1 IHC test Proportion Score (PS) and Intensity Score (IS
View article: Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages Open
View article: FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Purpose: In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non–basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from ad…
View article: Oncological needs in transgender patients
Oncological needs in transgender patients Open
Transgender people encounter unique health disparities in oncology. They face substantial barriers in accessing healthcare that are exaggerated by bias/discrimination from healthcare professionals and systems, and socio-economic marginalis…
View article: Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression Open
This review offers an expert perspective on biomarkers, CDK4/6 inhibitor efficacy, and therapeutic approaches for managing hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-) advanced breast cancer (ABC…
View article: Univentricular Heart in Adults: Clinical Outcomes, Diagnostic Challenges, and Therapeutic Approaches
Univentricular Heart in Adults: Clinical Outcomes, Diagnostic Challenges, and Therapeutic Approaches Open
Univentricular heart is a rare and complex congenital heart defect characterized by the presence of a single functional ventricular chamber. While significant advancements in pediatric surgical interventions have improved the survival of p…
View article: First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN Open
View article: Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes Open
Purpose The prognostic utility and biological correlates of neutrophil to lymphocyte ratio (NLR), a potential biomarker of the balance between immune response and the inflammatory status, are still uncertain in breast cancer (BC). Methods …
View article: Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study
Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study Open
Background Trimetazidine (TMZ) has shown anti-ischemic and anti-anginal effects by shifting the production of ATP from free fatty acid to glucose oxidation. Few clinical studies have looked at the effectiveness and tolerability of a new pr…
View article: Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) Open
View article: 2142P Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
2142P Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU) Open
View article: Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia
Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia Open
Objectives Hereditary breast and ovarian cancer (HBOC) follows an autosomal dominant inheritance pattern of cancer susceptibility genes. The risk of developing this disease is primarily associated with germline mutations in the BRCA1 and B…
View article: Variantes genéticas recurrentes y priorización de variantes de significado clínico desconocido asociadas al síndrome de cáncer de mama y ovario hereditario en familias de la Región de Murcia
Variantes genéticas recurrentes y priorización de variantes de significado clínico desconocido asociadas al síndrome de cáncer de mama y ovario hereditario en familias de la Región de Murcia Open
Resumen Objetivos El síndrome de cáncer de mama y ovario hereditario (SCMOH) presenta un patrón de herencia autosómica dominante en genes de susceptibilidad al cáncer y su riesgo está principalmente vinculado a mutaciones germinales en BRC…
View article: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) Open
View article: A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients Open
Background Up to 30% of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NCT) will relapse. Our objective was to analyze the predictive capacity of several markers associated with immune response and cell proliferation co…
View article: Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer
Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer Open
Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this study was to investigate the predictive and …
View article: Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study Open
Introduction There is currently no validated score capable of classifying cancer-associated pulmonary embolism (PE) in its full spectrum of severity. This study has validated the EPIPHANY Index, a new tool to predict serious complications …